{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:17:36Z","timestamp":1794057456623,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004791","name":"Scientific Research Seed Fund of Peking University First Hospital","doi-asserted-by":"publisher","award":["2018SF049"],"award-info":[{"award-number":["2018SF049"]}],"id":[{"id":"10.13039\/501100004791","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clinre.2020.03.026","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T07:59:51Z","timestamp":1586937591000},"page":"874-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators"],"prefix":"10.1016","volume":"44","author":[{"given":"Jian-Dan","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Tian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinre.2020.03.026_bib0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.03.026_bib0165","doi-asserted-by":"crossref","first-page":"8959103","DOI":"10.1155\/2019\/8959103","article-title":"Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis","volume":"2019","author":"Zhang","year":"2019","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"10.1016\/j.clinre.2020.03.026_bib0170","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","article-title":"Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis","volume":"42","author":"Nakamura","year":"2005","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2020.03.026_bib0175","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0034-1383732","article-title":"Clinical significance of autoantibodies in primary biliary cirrhosis","volume":"34","author":"Nakamura","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.clinre.2020.03.026_bib0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Electronic address European Association for the Study of the L. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2020.03.026_bib0185","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2020.03.026_bib0190","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2020.03.026_bib0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cld.2007.11.013","article-title":"Medical treatment of cholestatic liver disease","volume":"12","author":"Paumgartner","year":"2008","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1016\/j.clinre.2020.03.026_bib0200","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","article-title":"Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis","volume":"44","author":"Azemoto","year":"2009","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2020.03.026_bib0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.clinre.2020.03.026_bib0210","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.clinre.2020.03.026_bib0215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.clinre.2020.03.026_bib0220","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/MD.0000000000000104","article-title":"Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis","volume":"93","author":"Fang","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.clinre.2020.03.026_bib0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12072-017-9819-9","article-title":"A brief review on prognostic models of primary biliary cholangitis","volume":"11","author":"Chen","year":"2017","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.clinre.2020.03.026_bib0230","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.03.026_bib0235","first-page":"10","article-title":"Diagnostic Accuracy of Non-Invasive Fibrosis Models to Detect Change in Fibrosis Stage","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.clinre.2020.03.026_bib0240","first-page":"1","article-title":"Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis","volume":"15","author":"Brener","year":"2015","journal-title":"Ont Health Technol Assess Ser"},{"issue":"6","key":"10.1016\/j.clinre.2020.03.026_bib0245","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2020.03.026_bib0250","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"issue":"3","key":"10.1016\/j.clinre.2020.03.026_bib0255","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.clinre.2020.03.026_bib0260","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.clinre.2020.03.026_bib0265","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clinre.2020.03.026_bib0270","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","article-title":"Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study","volume":"29","author":"Wolfhagen","year":"1998","journal-title":"J Hepatol"},{"issue":"4\u20135","key":"10.1016\/j.clinre.2020.03.026_bib0275","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gcb.2010.02.004","article-title":"Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone","volume":"34","author":"Rabahi","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"issue":"4","key":"10.1016\/j.clinre.2020.03.026_bib0280","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.03.026_bib0285","doi-asserted-by":"crossref","first-page":"139763","DOI":"10.1155\/2013\/139763","article-title":"Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy","volume":"2013","author":"Tsochatzis","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clinre.2020.03.026_bib0290","first-page":"10","article-title":"Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis","author":"Joshita","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2020.03.026_bib0295","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clinre.2020.03.026_bib0300","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.clinre.2020.03.026_bib0305","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3109\/00365521.2015.1132337","article-title":"Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis","volume":"51","author":"Juliusson","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clinre.2020.03.026_bib0310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bpg.2018.06.004","article-title":"Improving prognosis in primary biliary cholangitis - Therapeutic options and strategy","volume":"34\u201335","author":"Harms","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120301017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120301017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:29:48Z","timestamp":1761895788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740120301017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2210740120301017"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2020.03.026","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2020.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}